Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 14,746 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pulmonary Clear all

Conditions: Cystic Fibrosis
Interventions: novolog insulin, levemir insulin, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 10 Years to 25 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Non-small Cell Lung Cancer
Interventions: Trabedersen, Pembrolizumab; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions: Recombinant Interleukin-12; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19, Cancer
Interventions: Hydroxychloroquine, Placebo, Radiation therapy; Drug · Other · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cystic Fibrosis
Interventions: Linezolid; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prediabetes, Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
Interventions: CGM Dynamic Index (CDI); Device
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 27
States / cities: Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more

Conditions: Asthma, Allergic Asthma, Non-allergic Asthma
Interventions: Levocetirizine 0.5 Mg/mL Oral Solution; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 7 Years to 17 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Pulmonary Hypertension
Interventions: Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo; Drug · Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more

Conditions: Pulmonary Embolism, Venous Thromboembolism, Metabolomics, Oxygen Inhalation Therapy
Interventions: Oxygen Therapy, Non-rebreather mask; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more

Conditions: PAH
Interventions: 75mg CXA-10, 150mg CXA-10, Placebo; Drug · Other
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Left Ventricular Dysfunction, Right Ventricular Dysfunction, Pulmonary Hypertension, Heart Valve Diseases
Interventions: Not listed
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Asthma
Interventions: Fluticasone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Asthma, Asthma Attack, Asthma Exacerbations
Interventions: Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application; Drug · Other
Lead sponsor: DARTNet Institute; Government
Eligibility: 13 Years to 75 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more

Conditions: Pulmonary Artery Hypertension
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Neer Infrared Spectroscopy; Device
Lead sponsor: Keck School of Medicine of USC; Other
Eligibility: 1 Hour to 24 Hours
Enrollment: 50 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension, Pulmonary
Interventions: ambrisentan, tadalafil; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more

Conditions: Asthma
Interventions: Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more

Conditions: Lung Cancer
Interventions: semi-structured interviews; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Extensive Stage Lung Small Cell Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 411
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 296 more

Conditions: COPD
Interventions: SpiroPD; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-small Cell Lung Cancer
Interventions: Tepotinib, Osimertinib; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 49
States / cities: Yuma, Arizona • Fountain Valley, California • Long Beach, California + 43 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 92
States / cities: Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more

Search by objective public record fields.

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

Interleukin-12 in Treating Patients With Cancer in the Abdomen

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

Pharmacokinetics of Linezolid in Children With Cystic Fibrosis

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

Tezepelumab COPD Exacerbation Study

Characterization of the Role of Histamine in Children With Asthma

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Supplemental Oxygen in Pulmonary Embolism (SO-PE)

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System

Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in Asthma

Individualizing Treatment for Asthma in Primary Care (Full Study)

Vascular Subphenotypes of Lung Disease in HIV & COPD

Application of Lung Near-Infrared Spectroscopy (NIRS) in Preterm Infants

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Feasibility of At-Home Handheld Spirometry

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation